Literature DB >> 3479047

Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.

G L Drusano1, K I Plaisance, A Forrest, C Bustamante, A Devlin, H C Standiford, J C Wade.   

Abstract

We ascertained the pharmacokinetics of imipenem in febrile granulocytopenic cancer patients. The values observed were both different from and significantly more variable than those observed in normal volunteers. Free drug concentrations exceeded the MIC for 90% of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus strains for greater than 6 h. The MIC for 90% of Pseudomonas aeruginosa strains was exceeded for 4 h. Because imipenem induces a 2-h postantibiotic effect in P. aeruginosa, it is promising as single-agent empiric therapy in this setting.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3479047      PMCID： PMC174953          DOI： 10.1128/AAC.31.9.1420

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model.

Authors:  J J Mordenti; R Quintiliani; C H Nightingale
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

2.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

3.  Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison.

Authors:  G L Drusano; P A Ryan; H C Standiford; M R Moody; S C Schimpff
Journal:  Rev Infect Dis       Date:  1984 May-Jun

4.  Multiple-dose pharmacokinetics of imipenem-cilastatin.

Authors:  G L Drusano; H C Standiford; C Bustamante; A Forrest; G Rivera; J Leslie; B Tatem; D Delaportas; R R MacGregor; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

5.  Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability.

Authors:  D A Gravallese; D G Musson; L T Pauliukonis; W F Bayne
Journal:  J Chromatogr       Date:  1984-09-14

6.  Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

7.  Imipenem therapy of Pseudomonas aeruginosa bacteraemia in neutropenic rats.

Authors:  D E Johnson; F M Calia; M J Snyder; J W Warren; S C Schimpff
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

8.  Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer.

Authors:  J C Wade; H C Standiford; G L Drusano; D E Johnson; M R Moody; C I Bustamante; J H Joshi; C deJongh; S C Schimpff
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

9.  Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice.

Authors:  A U Gerber; W A Craig; H P Brugger; C Feller; A P Vastola; J Brandel
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

10.  Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.

Authors:  H C Standiford; G L Drusano; C I Bustamante; G Rivera; A Forrest; B Tatem; J Leslie; M Moody
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191
View more
  11 in total

1.  In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

Authors:  D Szabó; A Máthé; Z Filetóth; P Anderlik; L Rókusz; F Rozgonyi
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

3.  Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.

Authors:  J G Coen van Hasselt; Matthew L Rizk; Mallika Lala; Cynthia Chavez-Eng; Sandra A G Visser; Thomas Kerbusch; Meindert Danhof; Gauri Rao; Piet H van der Graaf
Journal:  Br J Clin Pharmacol       Date:  2016-04-01       Impact factor: 4.335

4.  Disposition of ceftazidime in surgical patients with intra-abdominal infection.

Authors:  K L Heim-Duthoy; M P Bubrick; D M Cocchetto; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 5.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

6.  Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.

Authors:  K Heim-Duthoy; G Peltier; W Awni
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

7.  Pharmacokinetics of cefepime in patients with respiratory tract infections.

Authors:  J M Kovarik; J C ter Maaten; C M Rademaker; M Deenstra; I M Hoepelman; H C Hart; G R Matzke; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

8.  Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.

Authors:  J M Kovarik; A I Hoepelman; J M Smit; P A Sips; M Rozenberg-Arska; J H Glerum; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

9.  Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.

Authors:  F Lamoth; T Buclin; C Csajka; A Pascual; T Calandra; O Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

10.  Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.

Authors:  B J McGrath; K C Lamp; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.